NEW YORK (GenomeWeb) – The New York State Department of Health has approved BioTheranostics to offer its Breast Cancer Index to residents in the state, the company said today.

The molecular diagnostic test quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer. According to the San Diego firm, it is the only commercially available biomarker for estrogen receptor-positive breast cancer patients that accurately predicts early and late distant recurrence of the disease while also predicting the benefit from extended endocrine therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.